A Role for the Host in the Roadmap to Diabetes Stem Cell Therapy

Soria, Bernat; Montanya, Eduard; Martı́n, Franz; Hmadcha, Abdelkrim

doi:10.2337/dbi16-0003

Cited by 9 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Cell-based therapies represent a promising strategy for the treatment of CLI, helping to avoid amputation in these patients. [2][3][4][5][6][7] Particularly, mesenchymal stromal cells (MSCs) have shown significant therapeutic potential due to their fibrinolytic and antithrombogenic properties. [8][9][10][11][12] To date, there are more than 10 registered clinical trials (https://www.clinicaltrials.gov) using autolo-gous MSCs for the treatment of diabetes and its complications, and these cells are presumably safer and more effective than allogenic cells.…”

Section: Introductionmentioning

confidence: 99%

PDGF Restores the Defective Phenotype of Adipose-Derived Mesenchymal Stromal Cells from Diabetic Patients

et al. 2018

Self Cite

View full text Add to dashboard Cite

Diabetes is a chronic metabolic disorder that affects 415 million people worldwide. This pathology is often associated with long-term complications, such as critical limb ischemia (CLI), which increases the risk of limb loss and mortality. Mesenchymal stromal cells (MSCs) represent a promising option for the treatment of diabetes complications. Although MSCs are widely used in autologous cell-based therapy, their effects may be influenced by the constant crosstalk between the graft and the host, which could affect the MSC fate potential. In this context, we previously reported that MSCs derived from diabetic patients with CLI have a defective phenotype that manifests as reduced fibrinolytic activity, thereby enhancing the thrombotic risk and compromising patient safety. Here, we found that MSCs derived from diabetic patients with CLI not only exhibit a prothrombotic profile but also have altered multi-differentiation potential, reduced proliferation, and inhibited migration and homing to sites of inflammation. We further demonstrated that this aberrant cell phenotype is reversed by the platelet-derived growth factor (PDGF) BB, indicating that PDGF signaling is a key regulator of MSC functionality. These findings provide an attractive approach to improve the therapeutic efficacy of MSCs in autologous therapy for diabetic patients.

show abstract

Section: Introductionmentioning

confidence: 99%

PDGF Restores the Defective Phenotype of Adipose-Derived Mesenchymal Stromal Cells from Diabetic Patients

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cell‐based regimens are prospective for DFUs treatment, preventing amputation in sufferers 5,6 . Adipose tissue‐derived stem cells (ADSCs) are stemmed from lipid tissue matrix, which can possibly affect wound therapies in non‐diabetes situations, whereas they have no effects on diabetes sufferers 7 .…”

Section: Introductionmentioning

confidence: 99%

“…Cell-based regimens are prospective for DFUs treatment, preventing amputation in sufferers. 5,6 Adipose tissue-derived stem cells (ADSCs) are stemmed from lipid tissue matrix, which can possibly affect wound therapies in non-diabetes situations, whereas they have no effects on diabetes sufferers. 7 Elevated programmed cell death in stem cells is thought to damage wound repair in a diabetes rat model, 8 but the precise mechanism of apoptosis remains to be investigated.…”

Section: Introductionmentioning

confidence: 99%

Hsa_circ_0008500 inhibits apoptosis of adipose‐derived stem cells under high glucose through hsa‐miR‐1273h‐5p/ELK1 axis

Meng

Shen

Chu

et al. 2023

Environmental Toxicology

View full text Add to dashboard Cite

Preliminary researches have confirmed that the number of apoptosis of adipose tissue‐derived stem cells (ADSCs) in patients with diabetes is significantly increased, leading to a difficult healing wound. Increasing researches revealed that circular RNAs (circRNAs) can control apoptosis. However, it is still unclear whether and how circRNAs are critical for regulating ADSCs apoptosis. In this study, we utilized in vitro model in which ADSCs were cultivated with normal glucose (NG) (5.5 mM) or high glucose (HG) (25 mM) medium, respectively, and found that more apoptotic ADSCs were observed in HG medium comparing to ADSCs in NG medium. Furthermore, we found that hsa_circ_0008500 attenuated HG‐mediated ADSCs apoptosis. In addition, Hsa_circ_0008500 could directly interact with hsa‐miR‐1273h‐5p, acting as a miRNA sponge, which subsequently suppressed Ets‐like protein‐1(ELK1) expression, the downstream target of hsa‐miR‐1273h‐5p. Thus, these results indicated that targeting the hsa_circ_0008500/hsa‐miR‐1273h‐5p/ELK1 signaling pathway in ADSCs may be a potential target for repairing diabetic wounds.

show abstract